Why the study?
Antitumor therapies have increased survival in oncology patients, but cardiotoxicity such as cardiac insufficiency remains a significant cause of mortality.
This case highlights the risk of severe heart insufficiency as a cardiotoxic complication of combined osimertinib and bevacizumab therapy in lung cancer patients.
Answers are grounded in this paper and cite their sources.
Cardiac monitoring may be warranted with osimertinib plus bevacizumab; leaves open the incidence and prevention of combined cardiotoxicity.
Oncological and cardiovascular diseases are the main causes of mortality worldwide. The rate of these pathologies tends to increase as the population ages. The implementation of highly effective therapeutic schemes has led to a significant increase in the survival rate of oncology patients over the last decades. In many cases, the mortality rate in oncology patients who underwent effective treatment is caused by cardiovascular events arising as a consequence of aggressive antitumor treatment or pre-existing chronic cardiovascular diseases. Among cardiovascular complications that developed both during active treatment of the malignant neoplasm and in the longer term, literature most often mentions cardiac insufficiency. We present a clinical case of successful diagnosis and treatment of severe heart insufficiency caused by antitumor therapy with bevacizumab and osimertinib in a patient with cancer of the upper lobe of the right lung and metastases into the brain.
No takes yet. Share an insight, caveat, or question.
Zeynalovа et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: